[{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Forest Laboratories"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Forest Laboratories | US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Forest Laboratories | US Department of Veterans Affairs","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Forest Laboratories | US Department of Veterans Affairs"},{"orgOrder":0,"company":"Loma Linda University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Loma Linda University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loma Linda University \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Loma Linda University \/ Forest Laboratories"},{"orgOrder":0,"company":"University of Florida","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"University of Florida \/ Forest Laboratories"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Forest Laboratories | Shirley Ryan AbilityLab | Best Practice","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Forest Laboratories | Shirley Ryan AbilityLab | Best Practice","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ Forest Laboratories | Shirley Ryan AbilityLab | Best Practice"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brigham and Women's Hospital \/ Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Analgesic Solutions","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Analgesic Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Analgesic Solutions \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Analgesic Solutions \/ Forest Laboratories"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Michigan \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Forest Laboratories"},{"orgOrder":0,"company":"Albany Medical College","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Albany Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Insert","sponsorNew":"Albany Medical College \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Albany Medical College \/ Forest Laboratories"},{"orgOrder":0,"company":"Montefiore Medical Center","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"Montefiore Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montefiore Medical Center \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Montefiore Medical Center \/ Forest Laboratories"},{"orgOrder":0,"company":"Duke University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ Forest Laboratories"},{"orgOrder":0,"company":"Duke University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ Forest Laboratories"},{"orgOrder":0,"company":"University of Tennessee","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"University of Tennessee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tennessee \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Columbia University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Columbia University \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Norman Harden","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Forest Laboratories \/ Norman Harden","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Norman Harden"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Valera Bussell","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Valera Bussell","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Valera Bussell"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Mansoor Ahmed M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Mansoor Ahmed M.D.","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Mansoor Ahmed M.D."},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Spencer Dorn, MD, MPH","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Spencer Dorn, MD, MPH","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Spencer Dorn, MD, MPH"}]
Find Clinical Drug Pipeline Developments & Deals for ( -)-Milnacipran
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fibromyalgia.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Radiculopathy.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lupus Erythematosus, Systemic.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Autism Spectrum Disorder.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fibromyalgia.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fibromyalgia.
Details :
Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vulvodynia.
Reset All
